-
Core products are embroiled in lawsuits, products under development are difficult to fulfill, and BeiGene is approaching the brink of delisting
BeiGene (688235. SH) is a well-known innovative pharmaceutical company in the A-share market. From 2017 to the first half of 2024, the company's R&D investment in all phases was the highest among A-s ...